The development of chemotherapy regimens that include fluoropyrimidines, irinotecan and oxaliplatin has improved the overall survival (OS) of patients with colorectal cancer (CRC),[@b1] but many patients experience relapses after adjuvant treatment. In most patients, outcome cannot be predicted upfront because tumors with similar clinicopathological features can have significant differences in disease progression and treatment response.

The traditional model for development of CRC involves a progressive stepwise accumulation of genetic alterations.[@b2],[@b3] However, detailed molecular analyses have revealed that CRC is heterogeneous with regard to genetic and molecular alterations.

Molecular characteristics of the tumor play an important role in their response to treatment, and patients with microsatellite instable (MSI) cancers seem to have different prognosis and benefit from chemotherapy compared to microsatellite stable (MSS) patients.[@b4]--[@b8] MSI has been attributed predominantly to silencing of DNA mismatch repair (MMR) genes[@b9] and the terms MSI and dMMR (deficient MMR) have often been used interchangeably. Although a role of MMR proteins in influencing sensitivity to 5-fluorouracil (5FU) has been demonstrated,[@b8] MSI accounts for only 7--20% of all patients and cannot alone explain why some patients have significant benefit from chemotherapy while others do not. Further understanding and consideration of the molecular heterogeneity of CRC is essential to develop better classification methods that are associated with disease progression and response to therapies.

"What's new?Even when tumors look the same, they may behave differently. But patients can be treated more effectively if clinicians know how aggressively a cancer will progress or how well it will respond to treatment. That's why this study investigated molecular and genetic differences in colorectal cancer to find out how to distinguish different subtypes. They classified tumors into three categories based on three biological hallmarks: epithelial to mesenchymal transition, high mutation frequency, and proliferation. Each of the tumor types has a different prognosis and response to chemotherapy, and a patient's tumor type can help determine what treatment should be attempted."

Unbiased molecular classification of breast cancer into clinically relevant subtypes[@b10] has stimulated the development of treatment plans that are tailored to key oncogenic hallmarks in the tumor.[@b11] We only begin to appreciate similar hallmarks in CRC. Recently, several groups have reported molecular classifications beyond MSI, either by identifying patients with distinct CpG island methylation phenotypes (CIMP),[@b12] distinct mutation profiles[@b13] or distinct expression patterns.[@b14],[@b15] However, it is not yet clear how they relate to one another.

In a previous study, we observed three intrinsic subtypes based on the tumor's full genome expression patterns.[@b16] In this study, we aim to characterize these intrinsic subtypes to understand how their biology differs and how this influences the patient's outcome. The CRC intrinsic subtypes showed distinct features regarding the presence of oncogenic mutations, epithelial-to-mesenchymal transition (EMT), MMR phenotypes and cellular proliferation, and most importantly, showed a marked difference in prognosis and benefit from chemotherapy.

Methods
=======

Patients
--------

The CRC molecular subtypes were identified on a previously analyzed cohort of 188 CRC patients[@b16] and were validated in 543 stages II and III CRC patients (Table [1](#tbl1){ref-type="table"}, Supporting Information Table [S1](#sd1){ref-type="supplementary-material"}). Seventy-three percentage of the stage III patients in the validation cohort, for which treatment and outcome data was available, had been treated with 5FU-based chemotherapy, none with oxaliplatin. All tissue samples were collected from patients with appropriate informed consent. The study was performed in accordance with the ethical standards of the Helsinki Declaration and was approved by the Medical Ethical Board of the participating hospitals.

###### 

Molecular subtype characteristics

                         Development cohort   Validation cohort                                                                
  ---------------------- -------------------- ------------------- ---------- ---------- ----------- ---------- --------------- -----
  n                      65                   98                  25         117        336         90         *P* (X^2^)      731
  **Stage**                                                                                                                    
   I                     14% (9)              13% (13)            8% (2)                                       0.21            24
   II                    58% (38)             51% (50)            48% (12)   61% (71)   61% (204)   50% (45)                   420
   III                   26% (17)             30% (29)            40% (10)   39% (46)   39% (132)   50% (45)                   279
   IV                    2% (1)               6% (6)              4% (1)                                                       8
  **Age**                                                                                                                      
   \<70                  62% (40)             59% (58)            60% (15)   54% (63)   56% (188)   67% (60)   0.23            424
   ≥70                   38% (25)             41% (40)            40% (10)   46% (54)   44% (148)   33% (30)                   307
  **Gender**                                                                                                                   
   male                  40% (26)             47% (46)            48% (12)   48% (56)   64% (216)   50% (45)   **1.07E-03**    401
   female                60% (39)             53% (52)            52% (13)   52% (61)   36% (120)   50% (45)                   330
  **Location**                                                                                                                 
   left colon            31% (20)             61% (59)            52% (13)   31% (36)   64% (210)   56% (50)   **5.42E-16**    388
   right colon           63% (40)             29% (28)            36% (9)    67% (77)   27% (88)    41% (37)                   279
   rectum                6% (4)               10% (10)            12% (3)    2% (2)     9% (29)     3% (3)                     51
   *not available*       *(1)*                *(1)*               *(0)*      *(2)*      *(9)*       *(0)*                      13
  **Grade**                                                                                                                    
   low                   5% (3)               7% (7)              4% (1)     16% (19)   22% (75)    7% (6)     **5.23E-08**    111
   intermediate          72% (47)             80% (78)            64% (16)   44% (51)   62% (208)   66% (59)                   459
   high                  22% (14)             9% (9)              28% (7)    40% (47)   16% (53)    28% (25)                   155
   *not available*       *(1)*                *(4)*               *(1)*      *(0)*      *(0)*       *(0)*                      *6*
  **BRAF**                                                                                                                     
   activating mutation   47% (30)             0% (0)              21% (5)    21% (18)   2% (5)      13% (6)    **\<2.2E-16**   64
   wildtype / other      53% (34)             100% (91)           79% (19)   79% (69)   98% (223)   87% (40)                   476
   *not available*       *(1)*                *(7)*               *(1)*      *(30)*     *(108)*     *(44)*                     191
  **KRAS**                                                                                                                     
   activating mutation   25% (16)             26% (24)            35% (8)    46% (40)   28% (63)    31% (14)   0.08            165
   wildtype / other      75% (47)             74% (67)            65% (15)   54% (47)   72% (165)   69% (31)                   372
   *not available*       \(2\)                \(7\)               \(2\)      *(30)*     *(108)*     *(45)*                     194
  **PIK3CA**                                                                                                                   
   activating mutation   16% (10)             7% (6)              19% (4)    31% (17)   10% (18)    13% (3)    **9.23E-04**    58
   wildtype / other      84% (54)             93% (85)            81% (17)   69% (37)   90% (160)   87% (20)                   373
   *not available*       *(1)*                *(7)*               *(4)*      *(63)*     *(158)*     *(67)*                     300
  **Microsatellite**                                                                                                           
   stable (MSS)          63% (24)             100% (42)           90% (9)    44% (29)   98% (176)   90% (38)   **\<2.2E-16**   318
   instable (MSI)        37% (14)             0% (0)              10% (1)    56% (37)   2% (3)      12% (5)                    60
   *not available*       *(27)*               *(56)*              *(15)*     *(51)*     *(157)*     *(48)*                     354

Note: Percentages might not add up due to rounding

Molecular subtype classification
--------------------------------

Unsupervised clustering of whole genome data revealed three mayor groups with distinct gene expression pattern.[@b16] In this study, three distinct gene expression signatures representative for the molecular subtypes were used for sample classification (Table [2](#tbl2){ref-type="table"}). Signature development and sample classification is described in the Supporting Information Methods. Subtype-related gene expression measurements were performed on custom made Agilent microarrays.[@b16],[@b17] Microarray data are available in the Gene Expression Omnibus (GSE42284).

###### 

Gene signatures for classification of intrinsic CRC subtypes

  A-type         B-type       C-type                                           
  -------------- ------------ ------------ ----------- ---------- ------------ ----------
  HSPA4L         BG114486     VAPB         THBS2       GPSM1      LOC338328    ASPM
  SLC7A11        THC2669157   HNRNPA1L2    SPOCK1      VWF        ANKRD35      ORC6L
  NUDT6          QPRT         KIF3B        COL5A2      WISP1      KIAA1442     ZNF367
  ME1            PLA2G12B     ARFGEF2      FBLN1       SLIT3      THY1         NIPSNAP1
  DLG7           VAV3         PIWIL2       MGP         MC1R       FES          SPBC25
  KNTC2          PTPRO        FANCF        MXRA8       LAMB2      PGF          DIAPH3
  PRC1           RNF43        THC2644861   DCN         PCOLCE     MAP3K3       
  ECHS1          DDC          MOCS3        AEBP1       GPX7       GPSM3        
  DEPDC1         AXIN2        PIGU         BASP1       COX7A1     NPC2         
  ACADSB         C13orf18     CEP250       COL6A1      FGFR1      C14orf139    
  EIF4A2         TSPAN6       IFT52        COL1A2      AK021531   THC2532155   
  MREG           GGH          CXorf56      HTRA1       CALD1      C1orf198     
  NIPA1          PLAGL2       COBLL1       LOXL1       JAK3       FLT4         
  TIAL1          ACSL6        EPOR         COL5A1      TRO        SNRP70       
  URM1           RBP2         MAPRE2       FSTL1       TGFB3      KIAA1602     
  ZNF167         SLC6A4       SLC41A1      RARRES2     C1QTNF6    ELMO1        
  RARA           CTSL2        KCTD1        MSN         DTX3       RNF207       
  SNX21          AMACR        TRIB2        SPARC       NID2       POLE         
  NRXN2          POFUT1       PLK2         PDGFRB      COL18A1    CPSF6        
  ARFGAP1        CEBPA        RAMP1        TUBB6       SLC27A1    BCL2L14      
  PAPLN          PARD6B       LOC388610    SERPINF1    JAM2       TOM1L1       
  SMARCC2        PRDX5                     TPM2        EFHA2      SNRPC        
  AS3MT          SEPHS2                    CD248       GGTLA1     SYNCRIP      
  DKFZp547K054   C20orf142                 LGALS1      LAMC1      NDUFAB1      
  RGN            GPSM2                     CRYAB       ROBO4      RABL3        
  CTSF           SLC5A6                    CXCL12      IGFBP5     XRCC2        
  SORBS1         TP53RK                    CLDN5       FAM20C     NDUFA10      
  FCGRT          NCOA6                     LOC387763   TSPYL5     PA2G4        
  LARP6          C20orf111                 BNC2        VAMP5      RFC4         
  FHOD3          C20orf43                  OBSL1       FBXO17     ZNF695       
  NINL           HNF4A                     EVL         CLEC11A    PPARA        
  SRPX2          PSMA7                     COL6A3      PDLIM4     FBXO5        

Gene signatures specific for each of the three CRC intrinsic subtypes. Genes of each of the subtype profile (A-type 32 genes, B-type 53 genes and C-type 102 genes) are ranked (top to bottom and left to right) according to their relative up-regulation (green) or down-regulation (blue) compared to the other two subtypes.

Mutation analysis
-----------------

Mutations in *BRAF*(V600E), *KRAS* codons 12, 13 and 61 and *PIK3CA* exons 9 and 20 were assessed in cDNA by means of Sanger sequencing (Supporting Information Methods). In addition, 615 genes including all genes encoding the kinases (kinome) were analyzed by deep-sequencing on 73 patients (selected to include all subtypes, Supporting Information Table [S1](#sd1){ref-type="supplementary-material"}). Sample preparation, sequencing procedure (HiSeq2000, Illumina) and sequence data analysis variant calling (somatic point mutations and small insertions and deletions) are described in Supporting Information Methods.

MSI and dMMR phenotype assessment
---------------------------------

Assessment of MSI-status was performed according to the local standard at each participating hospital and is described in Supporting Information Methods. In addition, all samples were analyzed for their MSI/dMMR associated gene expression pattern by a previously reported 64-gene signature that accurately identifies CRC tumors that are MSI and/or show a dMMR phenotype[@b18] (Supporting Information Methods).

Readout of EMT phenotype
------------------------

Epithelial and mesenchymal characteristics were analyzed based on relative gene expression levels (median centered per gene) of marker genes known to be upregulated in mesenchymal and upregulated in epithelial cells. For each marker, a Student's *t*-test was performed for comparison of A versus B+C, B versus A+C and C versus A+B (development cohort).

In addition, gene expression of the previously reported EMT signature from Loboda *et al*. was investigated in the development cohort.[@b14] Ninety-six of their top 100 genes that were previously reported to be strongly associated with the EMT program were analyzed for differential expression across the three molecular subtypes, together with a multigene profile readout in which a higher EMT index represented a more mesenchymal phenotype (Supporting Information Methods).

Statistical and survival analysis
---------------------------------

All analyses and statistical tests were performed in R 2.14.1 ([www.r-project.org](http://www.r-project.org)), and were considered significant with a *p*-value \<0.05 (two-sided). Association of the subtypes with clinical and molecular makers was analyzed using a Pearson's Chi-squared test. Survival analysis was performed on the validation cohort using Cox proportional hazard models with two end-points: 10-year distant metastasis-free survival (DMFS) and 10-year cancer-related OS. Average follow-up time was 70 months (range 3--270 months). Investigation of benefit from 5FU-based adjuvant chemotherapy was performed by comparing OS rates of patients with and without chemotherapy. An interaction analysis was performed to analyze the differences in benefit between the subtypes based on 5-year OS. Most (76%) stage II patients were untreated, therefore this analysis was limited to the stage III patients of the validation cohort.

Results
=======

Three intrinsic molecular subtypes
----------------------------------

Unsupervised clustering of whole genome expression data revealed three intrinsic CRC molecular subtypes[@b16] (Fig. [1*a*](#fig01){ref-type="fig"}). To further characterize and understand the biological and clinical differences between these intrinsic subtypes, we have developed a diagnostic single sample classifier based on three "core" gene profiles representative for each of the subtypes (A-, B- and C-type) (Fig. [1*b*](#fig01){ref-type="fig"}, Table [2](#tbl2){ref-type="table"}). On the development cohort, 35% was classified as A-type, 52% as B-type and 13% as C-type CRC (Fig. [1*c*](#fig01){ref-type="fig"}, Table [1](#tbl1){ref-type="table"}), with a very high concordance of 97% compared to the unsupervised clustering method.[@b16]

![Single sample predictor for molecular subtype classification. *(a*) Unsupervised hierarchical clustering of the development cohort shows three distinct CRC intrinsic subtypes. (*b*) Gene signatures specific for A-type (32 genes), B-type (53 genes) and C-type (102 genes) CRC. Yellow indicates relative up-regulation and blue down-regulation of the genes across the 188 development samples. (*c*) A single sample classifier for identification of the three CRC subtypes.](ijc0134-0552-f1){#fig01}

Subtype classification and characteristics were confirmed in a validation cohort of 543 stages II and III CRC samples (Table [1](#tbl1){ref-type="table"}, Supporting Information Table [S1](#sd1){ref-type="supplementary-material"}). Twenty-two percent of patients were classified as A-type, 62% as B-type and 17% as C-type. Subtype classification was not associated with tumor stage (*p* = 0.21) or patient age (*p* = 0.23), but was significantly associated with tumor grade (*p* = 5.23e-8), gender (*p* = 1.07e-3) and microsatellite status (*p* \< 2.2e-16) (both cohorts combined, Table [1](#tbl1){ref-type="table"}). A significant difference in colon tumor location was observed (left vs. right colon, *p* = 1.04e-15; colon vs. rectum, *p* = 0.027).

Association with molecular markers
----------------------------------

Molecular characterization of the intrinsic subtype indicated that activating *BRAF*(V600E) mutations were unequally distributed between the subtypes (*p* = 1.9e-7) (Table [1](#tbl1){ref-type="table"}). Not only A-type (32%, both cohorts) but also C-type patients (16%) were enriched for *BRAF* mutations, while B-type patients were almost exclusively *BRAF* wild-type (98%). Subtype classification was also associated with activating *PIK3CA* mutations (*p* = 9.23e-4) but not associated with activating *KRAS* mutations (*p* = 0.08) (Table [1](#tbl1){ref-type="table"}). Combining the mutually exclusive *KRAS* and *BRAF* mutations, a highly significant association was observed with 68% A-type patients harbored an activating *BRAF* or *KRAS* mutation (Supporting Information Table [S2](#sd1){ref-type="supplementary-material"}).

The A-type group showed a significant higher proportion of MSI patients (49%, *p* \< 2.2e-16, both cohorts) while B-type patients were almost exclusively MSS (99%) (Table [1](#tbl1){ref-type="table"}). The association of A-type with MSI-status is in good agreement with other characteristics that have been observed before to be associated with MSI (*BRAF* mutations, right-sided tumor location, female gender and poor differentiation).[@b19] The lack of statistically significant association of A-type with stage might be explained by the absence of stages I and IV cancers in the validation cohort. However, the development cohort indicates that A-type patients might be more frequent in early stage cancer, in good agreement with better prognosis of A-type and MSI-patients.

Readout of the MSI/dMMR signature that is able to identify MSI and MSI-*like* tumors representative of a dMMR phenotype[@b18],[@b19] reinforced the strong MSI/dMMR characteristics of A-type patients with 68% showing a MSI/dMMR expression profile and confirmed the exclusive MSS and proficient MMR (pMMR) phenotype (99%) of B-type patients (Fig. [2*a*](#fig02){ref-type="fig"}). Although not enriched for MSI by the hospital assessment, a significant proportion of C-type patients (36%, *p* = 5.7e-4) showed a dMMR phenotype based on the MSI/dMMR-signature (Fig. [2*a*](#fig02){ref-type="fig"}).

![CRC subtypes are associated with MSI and dMMR phenotypes. (*a*) Readout of the MSI/dMMR signature[@b18] for the three CRC molecular subtypes. The symbols represent the binary MSI/dMMR (crosses) or MSS/pMMR (triangles) calls based on the signature indexes that are plotted on the *x*-axis. (*b*) Mutation frequency in the cancer kinome (615 genes) across the three subtypes: 23 A-type, 37 B-type and 13 C-type samples.](ijc0134-0552-f2){#fig02}

To validate the dMMR phenotype, 73 samples were deep-sequenced for their complete kinome. A- and C-type patients showed a significantly higher mutation frequency compared to B-type (*p* = 5.90e-5). On average, B-type patients showed a low mutation frequency of ten mutated genes of the 615 analyzed (1.6%), while the A-type and C-type groups harbored 38 (6.2%) and 26 (4.2%) mutated genes, respectively (Fig. [2*b*](#fig02){ref-type="fig"}).

These results are in agreement with a recent publication from the Cancer Genome Atlas Network (TCGA) that shows that some "hypermutated" cancers have high levels of microsatellite instability (MSI) while others are not and are classified as MSS/MSI-L by traditional MSI-methods.[@b13] This might explain why the C-type group has a high level of dMMR characteristics and high mutation rate but many patients are not classified as MSI by hospital methods.

Epithelial-to-mesenchymal characteristics
-----------------------------------------

Gene expression levels of known epithelial and mesenchymal markers were assessed in the subtypes (Fig. [3*a*](#fig03){ref-type="fig"}). In C-type cancers, almost all the mesenchymal markers, except *FLT1*, were significantly up-regulated, and three epithelial markers (*CDH1*, *EGFR* and *MET*) were down-regulated. In B-type, four of the five epithelial markers were up-regulated and three mesenchymal markers (*CDH2*, *FGFR1* and *TGFB1*) were down-regulated. A-type patients showed a significant reduced expression of two mesenchymal markers (*TWIST1* and *AXL*) but also a reduction in one of the epithelial markers (*CDH1*). These results indicated that C-type tumors have a more mesenchymal phenotype while A- and B-type tumors can be considered as epithelial.

![Molecular subtypes association with EMT characteristics. (*a*) Relative gene expression levels of eight mesenchymal and five epithelial marker in the three molecular subtypes. Significant levels are indicated for differential expression between the subtypes (pairwise Student's *t*-test). (*b*) Read-out of the EMT signature by Loboda *et al*.[@b14] across the molecular subtypes. Positive signature indexes are representative for a mesenchymal phenotype. (*c*) Receiver operating curve of C-type classification using the Loboda signature indexes. (*d*) Molecular subtype association of the epithelial and mesenchymal genes as presented by Loboda *et al*. Genes are shown according to the original clustering in Ref.[@b14]. Genes without a subtype indication showed no statistical significant differential expression.](ijc0134-0552-f3){#fig03}

The difference in epithelial and mesenchymal characteristics was confirmed by the recently published EMT signature by Loboda *et al*.[@b14] C-type patients showed a significantly higher (*p* \< 2.2e-16) EMT index representative of a more mesenchymal phenotype (Fig. [3*b*](#fig03){ref-type="fig"}). Classification of C-type patients by the Loboda signature showed an AUC of 0.92 (Fig. [3*c*](#fig03){ref-type="fig"}) with mesenchymal genes significant up-regulated in C-type samples and epithelial genes significant up-regulated in A-type or B-type samples (Fig. [3*d*](#fig03){ref-type="fig"}).

Prognosis
---------

Survival analysis on the validation cohort (*n* = 543, stages II and III) showed a significant difference in DMFS between the three subtypes (*p* = 0.004), with hazard ratios (HR) of 2.19 (*p* = 0.011) for B-type and 2.90 (*p* = 0.0024) for C-type patients compared to A-type (Fig. [4*a*](#fig04){ref-type="fig"}). C-type patients showed a significant reduced OS compared to A and B-types with a HR of 2.3 (*p* = 0.016) (Fig. [4*b*](#fig04){ref-type="fig"}).

![Prognostic value of molecular subtypes in stages II and III. Kaplan--Meier survival analysis of the three molecular subtypes in the validation cohort for (*a*) DMFS of all stages II and III validation samples, (*b*) cancer-related OS of all stages II and III, (*c*) in MSI patients (MSI status is based on the hospital MSI testing or, if not available, on the previously reported MSI gene signature,[@b18] see Methods section for details) and (*d*) *BRAF* wildtype patients. Survival curves of A-, B- and C-type samples are indicated in blue, gray and orange, respectively.](ijc0134-0552-f4){#fig04}

Although MSI status is generally associated with a good prognosis, we observed significant differences in DMFS between the subtypes (*p* = 0.034) with A-type-MSI patients having a very good prognosis but with C-type-MSI-patients having a poor prognosis (93 and 50% 10-year DMFS, respectively) (Fig. [4*c*](#fig04){ref-type="fig"}). A multivariate analysis, including MSI, *BRAF*, stage, gender and NCCN classification,[@b20] confirmed that the subtype classification has independent prognostic value (Supporting Information Table [S3](#sd1){ref-type="supplementary-material"}) that is additive to MSI and *BRAF* assessment (Fig. [4*d*](#fig04){ref-type="fig"}).

Adjuvant chemotherapy benefit
-----------------------------

To analyze chemotherapy benefit, outcome of 222 stage III patients were compared. Of these patients, 161 received adjuvant 5FU chemotherapy and 61 received no adjuvant chemotherapy. In accordance with data from clinical trials,[@b21] treatment with 5FU-based chemotherapy was beneficial when compared with no additional treatment (HR 0.55, *p* = 0.033). The benefit from chemotherapy was different in the three molecular subtypes (Figs. [5*a*](#fig05){ref-type="fig"}--[5*d*](#fig05){ref-type="fig"}). Stage III patients with A- and B-type tumors showed a benefit in OS with a HRs of 0.39 (*p* = 0.18) and 0.42 (*p* = 0.014), respectively; the difference not being statistically significant in A-type due to lower number of patients in this type. In contrast to the epithelial-like A- and B-type patients, the mesenchymal-like C-type patients showed no benefit from chemotherapy treatment (HR 1.4, *p* = 0.542). An interaction analysis between subtypes and chemotherapy with OS as endpoint confirmed that chemotherapy response was significantly different between the molecular subtypes (*p* = 0.017, Fig. [5*d*](#fig05){ref-type="fig"}). Since MSI has been associated with nonresponsiveness to 5FU, the analysis for C-type patients was repeated for MSS patients only. C-type-MSS tumors again showed no benefit from chemotherapy (HR 1.08, *p* = 0.95) (data not shown).

![Molecular subtypes differ for their response to chemotherapy. Kaplan--Meier survival analysis (OS) between patients (validation cohort) treated with and without chemotherapy for (*a*) A-type, (*b*) B-type and (*c*) C-type CRC. (*d*) Adjuvant chemotherapy benefit for the subtypes as measured by the difference in 5-year OS. (*e*) Gene expression boxplots of two proliferation markers *KI67* and AURKA across the three subtypes. *p*-Values indicate the significance of differential expression between C-type and A--B-types.](ijc0134-0552-f5){#fig05}

We hypothesized that the difference in chemotherapy benefit might be related to the proliferative activity of the molecular subtypes. Relative gene expression levels of two proliferative markers, Ki-67 (*MKI67*) and Aurora Kinase A (*AURKA*), showed a significantly reduced expression of both markers in C-type compared to A- and B-type tumors (*MKI67 p* = 6.06e-5, *AURKA p* = 4.53e-6, Student's *t*-test) (Fig. [5*e*](#fig05){ref-type="fig"}). Interestingly, A-type tumors showed the highest expression of *MKI67*, while *AURKA* was the strongest proliferative marker for B-type samples.

Discussion
==========

In this study, we have identified, described and validated three CRC intrinsic subtypes for their biological and clinical characteristics in a large set of tumors. As summarized in Figure [6](#fig06){ref-type="fig"}, subtype classification is largely driven by three hallmarks: EMT, higher mutation frequency resulting from dMMR and cellular proliferation.

![Classification model of CRC by A-, B- and C- subtypes. Classification model that discriminate three distinct subtypes: MMR-deficient epithelial (A-type), proliferative epithelial (B-type) and mesenchymal (C-type). A simplified model is shown for the main clinical and molecular characteristics of each of the three subtypes: baseline prognosis, 5FU-based chemotherapy response, epithelial or mesenchymal-like phenotypes, microsatellite status (MSI or MSS), MMR phenotype (deficient or proficient) and the associating *BRAF* mutation status and the tumor's proliferation rate as measured by *MKI67* and *AURKA* expression levels. This representation is a simplified model focused on the core-characteristics of each subtype.](ijc0134-0552-f6){#fig06}

A-type cancers consist of approximately 20--30% of all CRC and were found to be epithelial-like and to display a strong MSI phenotype linked to dMMR,[@b19] resulting in an overall high mutation rate including activating *BRAF* mutations. A-type patients have a good prognosis with some indication of benefit from 5FU-based adjuvant chemotherapy. Based on these features, A-types can be referred to as *MMR-deficient epithelial subtype*.

The most prevalent subtype, B-type or the *proliferative epithelial subtype*, includes 50--60% of tumors that show a strong epithelial phenotype. B-type tumors are almost exclusively MSS, *BRAF* wild-type and pMMR. Patients with this subtype show a relative poor baseline prognosis but, importantly, they benefit most significantly from adjuvant chemotherapy. This treatment benefit is likely caused by the high proliferative characteristics found in the subtype.

The third class, C-type, is the smallest but most distinct molecular subtype. C-type tumors have undergone an EMT and show dMMR characteristics. Patients with C-type tumors have a poor baseline prognosis and show no benefit from adjuvant 5FU treatment. The poor prognosis and unresponsiveness to chemotherapy is likely linked to their mesenchymal phenotype together with low proliferative activity. It has also been demonstrated by others that the mesenchymal phenotype is linked to low proliferative activity[@b22] and poor response to chemotherapy.[@b23] C-types can thus be referred to as *mesenchymal subtype*.

One of the hallmarks of the CRC intrinsic subtypes is the MSI or dMMR status. This characteristic is linked to the CIMP phenotype, right-sided location and to hypermutation.[@b13] Clinical studies have demonstrated that MSI rates vary with tumor stage, and in the adjuvant setting, MSI patients have been associated with longer survival than patients with MSS tumors.[@b7] However, the benefit of 5FU in this subgroup is debatable and different clinical studies give conflicting results.[@b5],[@b24],[@b25] The fact that MSI/dMMR patients are classified into two different molecular subtypes, one with a very good prognosis (A-type) and another with a very poor prognosis (C-type), might explain some of the conflicting results about chemotherapy benefit in MSI patients. It is of great interest to further investigate the relationship between MSI by traditional methods,[@b26] dMMR phenotype and molecular subtyping.

The second hallmark, EMT plays a prominent role in development and progression of CRC,[@b27] and might partially explain the difference in benefit from 5FU treatment between B-types (responsive) and C-types (resistant). This hypothesis is supported by an *in silico* validation of the ABC subtypes in a recently published study by Oh *et al*. In this study, two subtypes were identified in stages III and IV CRC that were prognostic and predictive for chemotherapy response.[@b28] Their subgroup with main benefit from chemotherapy is strictly associated with our B-type classification, while their nonresponsive subgroup is classified as either A- or C-type (Supporting Information Fig. [S2](#sd1){ref-type="supplementary-material"}). Other studies have shown that induction of EMT may play a role in acquiring resistance to oxaliplatin,[@b23] so it can be assumed that mesenchymal C-type patients are resistant to most if not all chemotherapies. Together, these results highlight the need for new approaches to treat this poor prognosis patient group.

This study was focused towards stages II and III CRC, therefore further validation of the subtype classification and its clinical relevance on a larger set of stage IV tumors is warranted. The three-way intrinsic colorectal classification demonstrated here is supported by the recently published results by TCGA.[@b13] In this study, 276 CRCs have been characterized by genome-scale analysis, and unsupervised classification based on gene expression levels also identified three distinct subclasses representative of an MSI/CIMP, CIN and an invasive phenotype. These phenotypes match with the respective characteristics of the A-, B- and C-type but here we added prognostic and chemotherapy benefit characteristics to the classification. Further independent studies are necessary to validate these findings and to investigate if the subgroups might divide into further clinical relevant subgroups.

The C-type-specific gene signature contains potential targets for development of new drugs and therefore might be useful in guiding new clinical studies for the treatment of this CRC subtype that is resistant to 5FU-based chemotherapy. For example, *SPARC* is upregulated in C-type CRC, and has been shown to be correlative with a response to nab-paclitaxel.[@b29],[@b30] Other interesting potential C-type targets are *JAK3*,[@b31] *CLDN5*[@b32] and *FLT4* (*VEGFR3*) for which multiple inhibitors are in development (*e.g*., cediranib, sunitinib, pazopanib, telatinib and sorafenib), and *FGFR1* for which cediranib and the dual inhibitor of *FGF* and *VEGF* brivanib have demonstrated antitumor activity.[@b33],[@b34] None of the agents have been used in patients with CRC with molecular selection and appropriate clinical trials are needed to find agents that can benefit C-type patients.

Classification based on these intrinsic subtypes will make it possible to expand and improve the intrinsic classification beyond standard molecular and immunohistochemical assessment and might help in the future to guide treatment in CRC patients.
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